Good morning, I have a question about a product: can PEG-MGF be injected into the muscle? I'd like to inject it into a bicep I injured some time ago. The information on the website isn't very clear: it says it can be injected near the target muscle, but what do you mean? Always under the skin or also into the muscle? Thanks.
Good morning, I have a question about a product: can PEG-MGF be injected into the muscle? I'd like to inject it into a bicep I injured some time ago. The information on the website isn't very clear: it says it can be injected near the target muscle, but what do you mean? Always under the skin or also into the muscle? Thanks.
PEG-MGF can be administered either subcutaneously or intramuscularly. When we mention injecting "near the target muscle," we generally mean either into the target muscle itself or into the surrounding area.
However, it is important to note that there is currently no strong scientific evidence showing that local administration provides superior results compared with systemic administration. Many users prefer to inject into or near the target muscle, especially when using PEG-MGF for recovery purposes, but this practice is largely based on anecdotal experience rather than controlled human studies.
1- Should PEG-MGF be injected within 30 or 60 minutes of finishing a workout?
2- For convenience, once recombined, can the products: PEG-MGF, TB-500, BPC-157, IPAMORELIN, and CJC 1295 with DAC remain in the preloaded syringes, or is it better to always keep them in the vial? I ask this because the syringes are plastic and the vial is glass.
1- Should PEG-MGF be injected within 30 or 60 minutes of finishing a workout?
2- For convenience, once recombined, can the products: PEG-MGF, TB-500, BPC-157, IPAMORELIN, and CJC 1295 with DAC remain in the preloaded syringes, or is it better to always keep them in the vial? I ask this because the syringes are plastic and the vial is glass.
The idea that PEG-MGF must be administered within 30–60 minutes after a workout comes from older discussions surrounding MGF, when it was believed that Mechano Growth Factor was released locally in muscle tissue following mechanical loading, and therefore administering exogenous MGF immediately after training was considered logical. However, this was largely a theoretical argument rather than a conclusion supported by strong evidence.
Furthermore, PEG-MGF differs from natural MGF in that it has a PEG group attached to it, significantly extending its circulation time in the body. In fact, this is precisely why PEG-MGF was developed. For that reason, the argument that one must hit a very narrow "anabolic window" appears even less convincing.
In practice, users typically choose one of three approaches:
immediately after training;
later in the evening after training;
at any convenient time on a training day.
I am not aware of any data showing a meaningful difference between these approaches.
About vials and syringes
As a general rule, it is preferable to store reconstituted peptides in their original glass vial rather than in preloaded syringes. Glass is the intended storage container and is generally more stable for longer-term storage.
Some users do preload syringes for short periods of time for convenience, but we would not recommend storing peptides in plastic syringes for extended periods. Whenever possible, keep the reconstituted product in the vial, refrigerated, and draw each dose as needed. This recommendation also applies to PEG-MGF, TB-500, BPC-157, Ipamorelin, and CJC-1295 DAC.
PEG-MGF can be administered either subcutaneously or intramuscularly. When we mention injecting "near the target muscle," we generally mean either into the target muscle itself or into the surrounding area.
However, it is important to note that there is currently no strong scientific evidence showing that local administration provides superior results compared with systemic administration. Many users prefer to inject into or near the target muscle, especially when using PEG-MGF for recovery purposes, but this practice is largely based on anecdotal experience rather than controlled human studies.
I have two more questions:
1- Should PEG-MGF be injected within 30 or 60 minutes of finishing a workout?
2- For convenience, once recombined, can the products: PEG-MGF, TB-500, BPC-157, IPAMORELIN, and CJC 1295 with DAC remain in the preloaded syringes, or is it better to always keep them in the vial? I ask this because the syringes are plastic and the vial is glass.
The idea that PEG-MGF must be administered within 30–60 minutes after a workout comes from older discussions surrounding MGF, when it was believed that Mechano Growth Factor was released locally in muscle tissue following mechanical loading, and therefore administering exogenous MGF immediately after training was considered logical. However, this was largely a theoretical argument rather than a conclusion supported by strong evidence.
Furthermore, PEG-MGF differs from natural MGF in that it has a PEG group attached to it, significantly extending its circulation time in the body. In fact, this is precisely why PEG-MGF was developed. For that reason, the argument that one must hit a very narrow "anabolic window" appears even less convincing.
In practice, users typically choose one of three approaches:
- immediately after training;
- later in the evening after training;
- at any convenient time on a training day.
I am not aware of any data showing a meaningful difference between these approaches.About vials and syringes
As a general rule, it is preferable to store reconstituted peptides in their original glass vial rather than in preloaded syringes. Glass is the intended storage container and is generally more stable for longer-term storage.
Some users do preload syringes for short periods of time for convenience, but we would not recommend storing peptides in plastic syringes for extended periods. Whenever possible, keep the reconstituted product in the vial, refrigerated, and draw each dose as needed. This recommendation also applies to PEG-MGF, TB-500, BPC-157, Ipamorelin, and CJC-1295 DAC.